OncoMatch/Clinical Trials/NCT07328854
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Is NCT07328854 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Cisplatin-based induction chemotherapy and Full course of PD-1 monoclonal antibody for nasopharyngeal carcinoma.
Treatment: Cisplatin-based induction chemotherapy · Full course of PD-1 monoclonal antibody — This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1-3N2M0, T3N0-1M0, STAGE II (AJCC/UICC TNM 9th edition)
Staged according to the 9th edition of the AJCC/UICC TNM classification as T1-3N2M0 or T3N0-1M0 (Stage II)
Prior therapy
Must have received: induction chemotherapy plus immunotherapy (gemcitabine, docetaxel, albumin-bound paclitaxel, paclitaxel, cisplatin) — induction
Imaging evaluation of treatment response after three cycles of GPP/TPP induction chemotherapy plus immunotherapy: CR or PR
Cannot have received: radiotherapy or surgery to local/regional lesions (excluding diagnostic surgery)
Patients whose local/regional lesions have undergone radiotherapy or surgery (excluding diagnostic surgery)
Lab requirements
Blood counts
wbc ≥ 4 × 10⁹/l, plt ≥ 100 × 10⁹/l, hgb ≥ 90 g/l
Kidney function
creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5 times the upper limit of normal
Liver function
total bilirubin, ast, alt ≤ 2.0 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify